An Ohio man filed a product liability case against Bristol-Myers Squibb and AstraZeneca in the U.S. District Court for the District of New Jersey, as he suffered coronary artery disease and congestive heart failure due to the alleged use of diabetes drug Onglyza. The plaintiff had been consuming Onglyza and Kombiglyze XR for several years to treat diabetes. In the complaint filed, he stated Onglyza makers purposely hid critical information about saxagliptin in the drug, which caused him serious and permanent heart injuries.
FDA proposed to add a new warning label for Onglyza in 2016, but even as clinical trials indicated potential dangers of Onglyza, the manufacturers released it into the market.
This lawsuit joins a growing number of similar lawsuits filed by individuals nationwide, who developed heart failure or other health risks due to the inadequate warnings. Onglyza lawsuits are consolidated in the U.S. District Court for the Eastern District of Kentucky, MDL Docket No. 2809, under District Judge Karen K. Caldwell, for coordinated pretrial proceedings.
